Abstract
Background Patient-reported outcome measures (PROM) have been shown to have important prognostic value after various cardiac interventions. We assessed the association between the change in Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) score after transcatheter aortic valve replacement (TAVR) and mortality.
Methods We included patients who underwent TAVR at Mayo Clinic between February 2012, and June 2022, who completed KCCQ-12 prior to and 30-45 days after the procedure. Patients were categorized into 3 groups: those who experienced significant (≥ 19 points; group-1), modest (1-19 points; group-2), and no improvement (≤ 0 points; group-3).
Results A total of 1,124 patients were included: 60.8% males; 97.6% Caucasian. Mean age was 79.4±8.3 years, KCCQ-12 score was 53.9±24.5, and median STS score was 4.9% (interquartile range 3.1-8.0). At 45 days, the mean change in KCCQ-12 score was 19±24 points: 46.3% (n= 520) of patients had a significant improvement in their KCCQ-12 score, while 33.4% (n= 375) and 20.4% (n = 229) had modest and no improvement, respectively. Median survival was higher in group-1 (5.7±0.2 years) compared to groups 2 and 3 (5.1±0.3 and 4.1±0.4 years, respectively; P<.001). Compared to patients in group 1, those in groups 2 and 3 had higher long-term risk-adjusted mortality (adjusted hazard ratio 1.64; 95%CI 1.28-2.10, and 2.44; 95%CI, 1.84-3.24, respectively).
Conclusion Patients who experience modest or no improvement in KCCQ-12 score after TAVR have substantially higher long-term mortality. Delta KCCQ-12 is a cost-effective, efficient tool that can identify patients at increased risk of death at long-term follow-up post-TAVR.
What is New?
This study documents the prognostic value of the Kansas City Cardiomyopathy Questionnaire 12 score in predicting long-term survival after TAVR.
Modest or no improvement in the Kansas City Cardiomyopathy Questionnaire 12 score after TAVR is associated with a considerably higher long-term mortality risk.
What are the Clinical Implications?
Changes in the Kansas City Cardiomyopathy Questionnaire 12 score may identify patients with higher residual mortality risk after transcatheter aortic valve replacement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mayo Clinic - Rochester's IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: All authors have no relevant conflicts to disclose.
Funding: No funding was obtained for this research.
Data Availability
De-identified data can be shared by the corresponding author upon request.
Nonstandard Abbreviations and Acronyms
- TAVR
- Transcatheter aortic valve replacement
- AS
- Aortic stenosis
- KCCQ
- Kansas City Cardiomyopathy Questionnaire
- STS
- Society of Thoracic Surgeons
